 |
424 Diseases |  |
809 Trials |
|
809 Trials |  |
14393 News |  |
| «12...153154155156157158159160161162163...235236» |
- leucovorin calcium / Generic mfg., fluorouracil / Generic mfg., Onivyde (nanoliposomal irinotecan) / Ipsen, PharmaEngine, Takeda, Servier
[VIRTUAL] Trends in real-world clinical outcomes among patients (pts) with metastatic pancreatic adenocarcinoma (mPDAC) treated with liposomal irinotecan based regimens in the United States (US). () - Apr 29, 2020 - Abstract #ASCO2020ASCO_4225;
Pts treated post-2018 experienced numerically longer rwTTF and rwOS than pts treated pre-2018. Research Funding: Ipsen
- leucovorin calcium / Generic mfg., fluorouracil / Generic mfg., Onivyde (nanoliposomal irinotecan) / Ipsen, PharmaEngine, Takeda, Servier
[VIRTUAL] Real-world use of liposomal irinotecan-based regimens among patients (pts) with metastatic pancreatic adenocarcinoma (mPDAC) in the United States (U.S.). () - Apr 29, 2020 - Abstract #ASCO2020ASCO_4214;
Median OS, TTF, and neutropenia were similar to those previously reported. As expected, pts receiving liposomal irinotecan in earlier lines had higher median OS and TTF.
- leucovorin calcium / Generic mfg., fluorouracil / Generic mfg.
[VIRTUAL] National Comprehensive Cancer Network (NCCN) category I/FDA-approved metastatic pancreatic adenocarcinoma (mPDAC) treatments in commercially insured patients: an analysis of inpatient (IP) and emergency room (ER) admissions. () - Apr 29, 2020 - Abstract #ASCO2020ASCO_4213;
LOS was similar across all regimens. Further studies are necessary to characterize the IP and ER HRU burden among mPDAC patients treated with approved regimens.
- [VIRTUAL] A multicenter chart review study of patients with metastatic pancreatic ductal adenocarcinoma receiving liposomal irinotecan after gemcitabine-based therapy. () - Apr 29, 2020 - Abstract #ASCO2020ASCO_4207;
Real-world data of the first 26 patients in this study show patients treated with liposomal irinotecan are older, sicker, and have had more lines of therapy than previously reported in RCT data. Research Funding: Ipsen Biopharmaceuticals
- [VIRTUAL] A real-world comparison of efficacy and toxicity of FOLFIRINOX and gemcitabine to nab-paclitaxel in treatment of advanced stage pancreatic cancer. () - Apr 29, 2020 - Abstract #ASCO2020ASCO_4202;
FFX is associated with an increased incidence of vomiting requiring hospitalization. FFX remains a preferred regimen in treating patients with good performance status regardless of age.
- leucovorin calcium / Generic mfg., fluorouracil / Generic mfg., Onivyde (nanoliposomal irinotecan) / Ipsen, PharmaEngine, Takeda, Servier
[VIRTUAL] Differentiation of liposomal irinotecan from dose-dense non-liposomal irinotecan in patient-derived pancreatic cancer xenograft tumor models. () - Apr 29, 2020 - Abstract #ASCO2020ASCO_4198;
N = 8 mice/group; aN = 4 mice. Collected b24 and c25 hours post-injection of third treatment cycle.
- leucovorin calcium / Generic mfg., fluorouracil / Generic mfg.
[VIRTUAL] Outcome of FOLFOX based chemotherapy in advanced pancreatobiliary cancers presenting with hyperbilirubinemia. () - Apr 29, 2020 - Abstract #ASCO2020ASCO_4079;
FOLFOX based chemotherapy is a feasible option and a hope for patients of advanced pancreatobiliary cancers presenting with hyperbilirubinemia with a tolerable toxicity profile and providing comparable PFS and OS to other chemotherapy drugs/ regimens used in non hyperbilirubinemic patients. Research Funding: None
- leucovorin calcium / Generic mfg., fluorouracil / Generic mfg., Lenvima (lenvatinib) / Eisai, Merck (MSD)
[VIRTUAL] Lenvatinib plus hepatic arterial infusion of modified FOLFOX regime in patients with advanced hepatocellular carcinoma. () - Apr 29, 2020 - Abstract #ASCO2020ASCO_4077;
A prospective large-scale trial is needed to justify these results. Research Funding: None
- [VIRTUAL] Hepatic artery infusion chemotherapy combined with apatinib and toripalimab in advanced hepatocellular carcinoma: Real-world data from a single center. () - Apr 29, 2020 - Abstract #ASCO2020ASCO_4076;
In patients with advanced HCC, treatment with strategically timed triple combination therapy of HAIC, apatinib, and toripalimab shows promising clinical benefit and safety. Research Funding: None
- Tyvyt (sintilimab) / Eli Lilly, leucovorin calcium / Generic mfg., fluorouracil / Generic mfg.
[VIRTUAL] Transarterial infusion chemotherapy (TAI) combined with Sintilimab in locally advanced, potentially resectable hepatocellular carcinoma (HCC). () - Apr 29, 2020 - Abstract #ASCO2020ASCO_4067;
TAI combined with Sintilimab attributed to high surgical conversion rate and good safety profile for locally advanced, potentially resectable HCC. Research Funding: The national natural science foundation of China
- envafolimab (KN035) / 3DMed, Tracon, leucovorin calcium / Generic mfg., fluorouracil / Generic mfg.
[VIRTUAL] Envafolimab plus chemotherapy in advanced gastric or gastroesophageal junction (G/GEJ) cancer. () - Apr 29, 2020 - Abstract #ASCO2020ASCO_4059;
Research Funding: 3D Medicines Co. Ltd.
- [VIRTUAL] Perioperative FLOT (fluorouracil, leucovorin, oxaliplatin and docetaxel) versus EOX/EOF (epirubicin, oxaliplatin and capecitabine or fluorouracil) for locally advanced, resectable gastric or gastro-oesophageal junction (GOJ) adenocarcinoma: A regional center experience. () - Apr 29, 2020 - Abstract #ASCO2020ASCO_4030;
Perioperative FLOT and EOX/EOF chemotherapy had similar pathological response, with higher completion of postoperative chemotherapy with FLOT regime. Research Funding: None
- leucovorin calcium / Generic mfg., fluorouracil / Generic mfg.
[VIRTUAL] Clinical implications of assumptions in cost-effectiveness analyses of systemic therapies for metastatic colorectal cancer. () - Apr 29, 2020 - Abstract #ASCO2020ASCO_3847;
Models generally focus on first-line treatment without considering the use of downstream treatments, suggesting these studies likely present biased results. This may impact the uptake of new systemic therapies.
- proTide 5-fluorouracil (NUC-3373) / NuCana BioMed, leucovorin calcium / Generic mfg.
[VIRTUAL] Pharmacokinetic analysis of NUC-3373 with and without leucovorin in patients with previously treated metastatic colorectal cancer (NuTide: 302 study). () - Apr 29, 2020 - Abstract #ASCO2020ASCO_3837;
- leucovorin calcium / Generic mfg.
[VIRTUAL] Outcomes in children with Down syndrome (DS) and B-lymphoblastic leukemia (B-ALL): A Children’s Oncology Group (COG) report. () - Apr 29, 2020 - Abstract #ASCO2020ASCO_2503;
Less toxic approaches such as immunotherapies and targeted therapies hold promise to improve outcomes in both these areas. U.S.
- doxorubicin hydrochloride / Generic mfg.
[VIRTUAL] Outcomes with reduced intensity therapy in a low-risk subset of children with National Cancer Institute (NCI) standard-risk (SR) B-lymphoblastic leukemia (B-ALL): A report from Children’s Oncology Group (COG) AALL0932. () - Apr 29, 2020 - Abstract #ASCO2020ASCO_2502;
P3
AALL0932 demonstrated that application of stringent risk criteria can identify a favorable B-ALL subgroup almost certain to be cured with either LR-M or LR-C, allowing physicians and families to select the optimal treatment approach in the future. Research Funding: U.S. National Institutes of Health, Other Foundation, Pharmaceutical/Biotech Company
- fluorouracil / Generic mfg., irinotecan / Generic mfg., GC-1118A / Green Cross
[VIRTUAL] Phase Ib/IIa study of GC1118 in combination with irinotecan or FOLFIRI in patients with metastatic solid tumors. (Poster Board 322) - Apr 29, 2020 - Abstract #ASCO2020ASCO_1542;
P1b/2a
Preliminary results of GC1118 and FOLFIRI as a 2nd line treatment in mCRC suggests promising antitumor activity and acceptable safety profile. Research Funding: Green Cross Corporation
- fluorouracil / Generic mfg., Thalomid (thalidomide) / Fujimoto, BMS, irinotecan / Generic mfg.
[VIRTUAL] A phase Ib study of simmitecan (LP) single-agent and in combination with 5-fluorouracil/leucovorin (5-FU/LV) or thalidomide (T) in patients with advanced solid tumor. (Poster Board 253) - Apr 29, 2020 - Abstract #ASCO2020ASCO_1475;
P1
A phase II study in pts with metastatic NEC is on-going to explore safety and efficacy of LP + 5-FU/LV regimen combined with toripalimab, an anti-PD-1 antibody. Research Funding: Shanghai HaiHe Pharmaceutical Co.,Ltd
- || Clinical, Journal, Real-World Evidence: Comparisons of Outcomes of Real-World Patients With Advanced Pancreatic Cancer Treated With FOLFIRINOX Versus Gemcitabine and Nab-Paclitaxel: A Population-Based Cohort Study. (Pubmed Central) - Apr 29, 2020
Research Funding: Shanghai HaiHe Pharmaceutical Co.,Ltd Our results showed that real-world patients with advanced pancreatic cancer treated with FOLFIIRNOX or GnP had comparable survival with different safety profile.
- | Avastin (bevacizumab) / Roche
Trial termination, Metastases: MRI in Predicting Response in Patients Receiving Combination Chemotherapy and Bevacizumab For Advanced or Metastatic Colorectal Cancer (clinicaltrials.gov) - Apr 28, 2020
P2, N=5, Terminated, Sponsor: Abramson Cancer Center of the University of Pennsylvania
Our results showed that real-world patients with advanced pancreatic cancer treated with FOLFIIRNOX or GnP had comparable survival with different safety profile. Completed --> Terminated; Due to Poor accrual
- | Bylantra (devimistat) / Cornerstone Pharma
Trial completion date, Combination therapy, Metastases: CPI-613 and Combination Chemotherapy in Treating Patients With Metastatic Pancreatic Cancer (clinicaltrials.gov) - Apr 28, 2020
P1, N=21, Active, not recruiting, Sponsor: Wake Forest University Health Sciences
Completed --> Terminated; Due to Poor accrual Trial completion date: Apr 2020 --> Jul 2020
- ||||||||| otilimab (GSK3196165) / GSK
Trial suspension, Combination therapy: contRAst 1: Efficacy and Safety of GSK3196165 Versus Placebo and Tofacitinib in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate (clinicaltrials.gov) - Apr 27, 2020
P3, N=1500, Suspended, Sponsor: GlaxoSmithKline
Trial completion date: Apr 2020 --> Jul 2020 Recruiting --> Suspended
- || When using FOLFIXIRI, do you use: irinotecan (165 mg/m2), oxaliplatin (85 mg/m2), leucovorin (200 mg/m2) 5-FU (3200 mg/m2 over 48 hrs), no 5-FU bolus? (Twitter) - Apr 27, 2020
- ||| Trial termination, Post-transplantation: Treatment of PTCL With Aggressive Induction Therapy Followed by Autologous SCT Using Denileukin Diftitox (Ontak) (clinicaltrials.gov) - Apr 27, 2020
P2, N=21, Terminated, Sponsor: University of California, San Francisco
Recruiting --> Suspended Active, not recruiting --> Terminated; Manufacturing shortage of both Diftitox and Doxil
- || oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg., fluorouracil / Generic mfg.
Clinical, Journal: A case of biopsy-proven oxaliplatin-induced acute tubulointerstitial nephritis with thrombocytopenia and anemia. (Pubmed Central) - Apr 26, 2020
It carries a reduced risk of acute kidney injury (AKI) compared to the previous platinum agents, including cisplatin and carboplatin...He suddenly developed shaking chills, fever, and hot flashes at the end of the 18th 5-fluorouracil (5-FU)/L-leucovorin/oxaliplatin administration, and was admitted to our hospital...The patient's renal function gradually improved, and 6 months later, it had returned to baseline. Our case demonstrates that we should consider not only ATN, but also ATIN, as potential presentations of oxaliplatin-induced AKI.
- |||| sirexatamab (DKN-01) / Leap Therap
New P2a trial, Combination therapy, Metastases: DisTinGuish: A Study of DKN-01 in Combination With Tislelizumab (clinicaltrials.gov) - Apr 26, 2020
P2a, N=72, Not yet recruiting, Sponsor: Leap Therapeutics, Inc.
- | leucovorin calcium / Generic mfg., fluorouracil / Generic mfg., irinotecan / Generic mfg.
Biomarker, Retrospective data, Journal: An Explorative Analysis of ABCG2/TOP-1 mRNA Expression as a Biomarker Test for FOLFIRI Treatment in Stage III Colon Cancer Patients: Results from Retrospective Analyses of the PETACC-3 Trial. (Pubmed Central) - Apr 25, 2020
In contrast, no significant differences were observed between the groups when patients received 5FUL alone. This study shows that the combination of ABCG2 and TOP1 gene expression significantly divided the Stage III colon cancer patients into two groups regarding benefit from adjuvant treatment with FOLFIRI but not 5FUL.
- || leucovorin calcium / Generic mfg., Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead
Clinical, Journal: HIV Viral Rebound Due to a Possible Drug-Drug Interaction between Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide and Calcium-Containing Products: Report of 2 Cases. (Pubmed Central) - Apr 24, 2020
Both cases resulted in rise in HIV RNA levels and emergence of M184 V mutation and resistance to elvitegravir and raltegravir. To the best of our knowledge, these 2 cases are the first reports of rapid emergence of mutation from coadministration of E/C/F/TAF and calcium.
- || Clinical, Retrospective data, Journal: Second-line FOLFIRI plus ramucirumab with or without prior bevacizumab for patients with metastatic colorectal cancer. (Pubmed Central) - Apr 24, 2020
The effectiveness of FOLFIRI + RAM as a second-line chemotherapy in patients with mCRC was in line with that reported in the previous RAISE phase III trial. The response was better in bevacizumab-naïve patients than those with first-line treatment that had included bevacizumab.
- | Avastin (bevacizumab) / Roche
Trial initiation date, Metastases: Toco-CoR: Tocotrienol and Bevacizumab in Metastatic Colorectal Cancer (clinicaltrials.gov) - Apr 23, 2020
P2, N=74, Not yet recruiting, Sponsor: Vejle Hospital
The response was better in bevacizumab-naïve patients than those with first-line treatment that had included bevacizumab. Initiation date: Mar 2020 --> Jun 2020
- | New P3 trial, Metastases: Triplet Combination of Cytotoxics as First-line Treatment for Metastatic Gastric Cancer (clinicaltrials.gov) - Apr 23, 2020
P3, N=388, Not yet recruiting, Sponsor: Sixth Affiliated Hospital, Sun Yat-sen University
- | New P1 trial, Metastases: I-FLOAT: Safety of Combining Irinotecan With 5-FU, Leucovorin/Folinic Acid, Oxaliplatin, and Docetaxel Chemotherapies (clinicaltrials.gov) - Apr 23, 2020
P1, N=54, Not yet recruiting, Sponsor: University of Chicago
- || oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg., fluorouracil / Generic mfg.
Clinical, Journal: Two Cases of Goblet Cell Carcinoid of Appendix Treated with Oxaliplatin-Based Adjuvant Chemotherapy (Pubmed Central) - Apr 23, 2020
The patient received capecitabine and oxaliplatin(CapeOX)as an adjuvant chemotherapy for 6 months. The patient has been free from recurrence for 22 months following surgery.
- || irinotecan / Generic mfg.
Clinical, Journal: Sex-dependent least toxic timing of irinotecan combined with chronomodulated chemotherapy for metastatic colorectal cancer: Randomized multicenter EORTC 05011 trial. (Pubmed Central) - Apr 23, 2020
Irinotecan timing was most critical for females, with grades 3-4 ranging from 55.2% of the patients (morning) to 29.4% (afternoon) for diarrhea, and from 25.9% (morning) to 0% (afternoon) for neutropenia. The study results support irinotecan administration in the morning for males and in the afternoon for females, in order to minimize adverse events without impairing efficacy.
- || fluorouracil / Generic mfg., irinotecan / Generic mfg.
Clinical, P2 data, Journal: Percutaneous Irreversible Electroporation in Locally Advanced and Recurrent Pancreatic Cancer (PANFIRE-2): A Multicenter, Prospective, Single-Arm, Phase II Study. (Pubmed Central) - Apr 22, 2020
P1/2
The study results support irinotecan administration in the morning for males and in the afternoon for females, in order to minimize adverse events without impairing efficacy. The target median OS was 11.6 months for participants receiving no induction chemotherapy or gemcitabine-based induction chemotherapy and 14.9 months for those receiving induction 5-fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX).
- || leucovorin calcium / Generic mfg., fluorouracil topical / Generic mfg., irinotecan / Generic mfg.
Review, Journal, BRCA Biomarker, PD(L)-1 Biomarker, IO biomarker: From state-of-the-art treatments to novel therapies for advanced-stage pancreatic cancer. (Pubmed Central) - Apr 22, 2020
In this Review, we describe the available data on the activity of these and other agents in patients with PDAC. Our discussion is structured according to the acronym 'PRIME' to organize the various treatment strategies currently undergoing evaluation in clinical trials: Pathway inhibition, alteration of DNA Repair pathways, Immunotherapy, cancer Metabolism and targeting the Extracellular tumour microenvironment.
- ||||||| pegilodecakin (LY3500518) / Eli Lilly
Trial completion, Combination therapy, Metastases: Sequoia: Study of Pegilodecakin (LY3500518) With FOLFOX Compared to FOLFOX Alone Second-line Tx in Participants With Metastatic Pancreatic Cancer (clinicaltrials.gov) - Apr 22, 2020
P3, N=567, Completed, Sponsor: Eli Lilly and Company
Our discussion is structured according to the acronym 'PRIME' to organize the various treatment strategies currently undergoing evaluation in clinical trials: Pathway inhibition, alteration of DNA Repair pathways, Immunotherapy, cancer Metabolism and targeting the Extracellular tumour microenvironment. Active, not recruiting --> Completed
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., sorafenib / Generic mfg.
Trial completion, Combination therapy, Metastases: Sorafenib + mFOLFOX for Hepatocellular Carcinoma (clinicaltrials.gov) - Apr 22, 2020
P2, N=40, Completed, Sponsor: Massachusetts General Hospital
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||| epacadostat (INCB024360) / Incyte
Trial suspension: Epacadostat (INCB024360) Added to Preoperative Chemoradiation in Patients With Locally Advanced Rectal Cancer (clinicaltrials.gov) - Apr 22, 2020
P1, N=39, Suspended, Sponsor: Washington University School of Medicine
Active, not recruiting --> Completed Recruiting --> Suspended
- || numidargistat (INCB001158) / Calithera
Trial completion date, Trial primary completion date, Combination therapy, Metastases: A Phase 1/2 Study of INCB001158 in Combination With Chemotherapy in Subjects With Solid Tumors (clinicaltrials.gov) - Apr 22, 2020
P1/2, N=249, Recruiting, Sponsor: Incyte Corporation
Recruiting --> Suspended Trial completion date: May 2020 --> Oct 2021 | Trial primary completion date: Mar 2020 --> Oct 2021
- || eftozanermin alfa (ABBV-621) / AbbVie, Apogenix
Trial completion date, Trial primary completion date: A Study of the Safety and Tolerability of ABBV-621 in Participants With Previously-Treated Solid Tumors and Hematologic Malignancies (clinicaltrials.gov) - Apr 22, 2020
P1, N=205, Recruiting, Sponsor: AbbVie
Trial completion date: May 2020 --> Oct 2021 | Trial primary completion date: Mar 2020 --> Oct 2021 Trial completion date: Dec 2021 --> Aug 2022 | Trial primary completion date: Feb 2021 --> Aug 2022
- | leucovorin calcium / Generic mfg., fluorouracil / Generic mfg., irinotecan / Generic mfg.
Journal: A fast method for the detection of irinotecan in plasma samples by combining solid phase extraction and differential pulse voltammetry. (Pubmed Central) - Apr 21, 2020
The suitability of the method proposed here for clinical applications was verified by determining the concentration of CPT-11 in plasma samples of an oncological patient, collected after 30 and 180 min from the infusion of the drug. Graphical abstract.
- | Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, Vectibix (panitumumab) / Amgen
Trial suspension: SULTAN: Improving SUrgery of Liver Metastases: a Trial of the Arterial Chemotherapy Network (clinicaltrials.gov) - Apr 21, 2020
P2, N=140, Suspended, Sponsor: UNICANCER
Graphical abstract. Recruiting --> Suspended
- | Vectibix (panitumumab) / Amgen
Trial suspension: PANIRINOX: Comparison FOLFIRINOX Panitumumab vs mFOLFOX6 Panitumumab in RAS/B-RAF Wild-type Metastatic Colorectal Cancer Patients (clinicaltrials.gov) - Apr 21, 2020
P2, N=209, Suspended, Sponsor: UNICANCER
Recruiting --> Suspended Recruiting --> Suspended
- | Erbitux (cetuximab) / Eli Lilly, Zelboraf (vemurafenib) / Roche
Trial primary completion date, Metastases: Cetuximab and Vemurafenib Plus FOLFIRI for BRAF V600E Mutated Advanced Colorectal Cancer (IMPROVEMENT) (clinicaltrials.gov) - Apr 20, 2020
P2, N=30, Recruiting, Sponsor: Shanghai Changzheng Hospital
Recruiting --> Suspended Trial primary completion date: Aug 2019 --> Dec 2020
- | Imfinzi (durvalumab) / AstraZeneca
Trial suspension: ARION: Association of Radiochemotherapy and Immunotherapy for the Treatment of Unresectable Oesophageal caNcer (clinicaltrials.gov) - Apr 20, 2020
P2, N=120, Suspended, Sponsor: UNICANCER
Trial primary completion date: Aug 2019 --> Dec 2020 Recruiting --> Suspended
- | Trial suspension, Metastases: GEMPAX: Gemcitabine and Paclitaxel vs Gemcitabine Alone After FOLFIRINOX Failure in Metastatic Pancreatic Ductal Adenocarcinoma (clinicaltrials.gov) - Apr 20, 2020
P3, N=210, Suspended, Sponsor: UNICANCER
Recruiting --> Suspended Recruiting --> Suspended
- | Loqtorzi (toripalimab-tpzi) / Shanghai Junshi Biosci, Coherus Biosci
New P2 trial, Metastases: Toripalimab Combined With FLOT Neoadjuvant Chemotherapy in Patients With Resectable Gastric Cancer (clinicaltrials.gov) - Apr 20, 2020
P2, N=35, Recruiting, Sponsor: Tianjin Medical University Cancer Institute and Hospital
- ||| monalizumab (IPH2201) / AstraZeneca, Innate, Imfinzi (durvalumab) / AstraZeneca
Enrollment closed, IO biomarker, Metastases: A Study of Durvalumab (MEDI4736) and Monalizumab in Solid Tumors (clinicaltrials.gov) - Apr 20, 2020
P1/2, N=383, Active, not recruiting, Sponsor: MedImmune LLC
Recruiting --> Suspended Recruiting --> Active, not recruiting
- | Journal, Benefit-risk assessment: Risk Benefit of FOLFIRI Plus Ramucirumab as Third-line and Later-line Treatment of Metastatic Colorectal Cancer. (Pubmed Central) - Apr 16, 2020
F-RAM as third-line and later-line treatment for mCRC has a poor risk benefit. TAS-102 should be given priority over F-RAM.